Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Bosnia | Bulgaria | Chile | Colombia | Croatia | Czech | Dominican Republic | Ecuador | Egypt | France | Greece | Hong Kong | Indonesia | Italy | Jordan | Korea | Lebanon | Mexico | Morocco | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | Singapore | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Cairo University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Brain Diseases|Hepatic Encephalopathy|Colitis, Ulcerative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT05988528 | P3 |
Recruiting |
Colitis, Ulcerative |
2027-08-20 |
|
CL (3202) | P3 |
Recruiting |
Hepatic Encephalopathy|Brain Diseases |
2024-12-01 |